Description

This episode shifts the focus from symptoms and quality of life to biochemical and imaging-based endpoints in primary biliary cholangitis (PBC). Experts explore the relevance of alkaline phosphatase response, non-invasive fibrosis assessment, and composite scores like GLOBE and UK-PBC. Are these markers enough in the era of second-line therapies? Tune in for insights into trial design, drug approval, and future directions.

• Moderator: Marco Carbone
• Gilead Representative: Christophe Hézode
• Mirum Representative: Tiago Nunes
• Ipsen Representative: Marwan Sleiman

This EASL Studio is supported by Ipsen, Gilead Sciences Europe Ltd and Mirum.